Vandetanib Completed Phase 2 Trials for Non Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00252746ZD6474 Phase IIa Dose Finding Multicentre Study